Pilot study of hydrolytically activated paclitaxel prodrug therapy in patients with progressive malignancies

Current Therapeutic Research - Clinical and Experimental

Volumn 63, Issue 4, 2002, Pages 247-262

  Wrasidlo, Wolfgang ^a   Niethammer, Andreas ^a   Deger, Serdar ^a   Sehouli, Jalid ^a   Kulozik, Andreas ^a   Geilen, Wilhelm ^a   Henze, Günter ^a   Gaedicke, Gerhard ^a   Lode, Holger N ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Charit Medical University   (Germany)

Author keywords

Cancer; Chemotherapy; Paclitaxel; Pharmacokinetics; Prodrug

Indexed keywords

2',7 [BIS(2',3' ISOPROPYLIDENEGLYCEROL CARBONOXYL)]PACLITAXEL; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN DERIVATIVE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PRODRUG; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALOPECIA; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG STABILITY; DRUG STORAGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROLYSIS; LEUKOCYTE COUNT; LIVER TOXICITY; MALE; NASOPHARYNX CARCINOMA; NEUROBLASTOMA; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RHABDOMYOSARCOMA; SLOW DRUG RELEASE; TREATMENT OUTCOME; UROGENITAL TRACT TUMOR;

EID: 0036264249     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(02)80030-3     Document Type: Article

References (32)

1. Paclitaxel (Taxol)
2. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group results
3. Phase II trial of taxol in patients with metastatic renal cell carcinoma
4. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
5. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
6. Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer
7. Post-operative adjuvant therapy for non-small-cell lung cancer
8. Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group
9. Taxol: Mechanisms of action and resistance
10. Promotion of microtubule assembly in vitro by taxol
11. Taxol induces the formation of unusual arrays of cellular microtubules in colchicine-pretreated J774.2 cells
12. Taxol binds to cellular microtubules
13. Taxol-induced polymerization of purified tubulin: Mechanism of action
14. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations
15. Taxol: A novel radiation sensitizer
16. Relationship between the structure of Taxol and other taxanes on induction of tumor necrosis factor-alpha gene expression and cytotoxicity
17. Taxanes in combined-modality therapy for solid tumors
18. An overview of experience with Taxol (paclitaxel) in the U.S.A.
19. Hypersensitivity reactions from Taxol
20. Clinical toxicities encountered with paclitaxel (Taxol)
21. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients
22. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors
23. Manipulation and exploitation of the tumour environment for therapeutic benefit
24. Peripheral neuropathy from Taxol and cisplatln combination chemotherapy: Clinical and electrophyslologlcal studies
25. Neurotoxicity of Taxol
26. Prodrugs in cancer chemotherapy
27. Genetic instability induced by the tumor microenvironment
28. Regulation of intracellular pH in subpopulations of cells derived from spheroids and solid tumours
29. Use of hypoxia-directed drugs in the therapy of solid tumors
30. Acid pH in tumors and its potential for therapeutic exploitation
31. Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumor activity and water solubility
32. Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors